| scholarly article | Q13442814 |
| P50 | author | Robert G. Webster | Q2159171 |
| P2093 | author name string | L V Gubareva | |
| G J Hart | |||
| K G Murti | |||
| R Bethell | |||
| C R Penn | |||
| P2860 | cites work | Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding | Q24676721 |
| Characterization of temperature sensitive influenza virus mutants defective in neuraminidase | Q27865285 | ||
| Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action | Q27867721 | ||
| Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution | Q28131812 | ||
| Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase) | Q28368367 | ||
| 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro | Q28378588 | ||
| Rational design of potent sialidase-based inhibitors of influenza virus replication | Q29616647 | ||
| The determination of enzyme inhibitor constants | Q29618526 | ||
| Emergence and apparent transmission of rimantadine-resistant influenza A virus in families | Q30460018 | ||
| Plaque inhibition assay for drug susceptibility testing of influenza viruses | Q33729018 | ||
| Structure of the catalytic and antigenic sites in influenza virus neuraminidase | Q34249841 | ||
| Influenza virus neuraminidase: structure, antibodies, and inhibitors | Q34318113 | ||
| Crystallographic detection of a second ligand binding site in influenza virus hemagglutinin | Q36771495 | ||
| Influenzavirus neuraminidase and neuraminidase-inhibition test procedures | Q36786074 | ||
| Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. | Q36864763 | ||
| Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). | Q37513512 | ||
| Infectious entry pathway of influenza virus in a canine kidney cell line | Q41439180 | ||
| Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid | Q42282978 | ||
| Biologic potential of amantadine-resistant influenza A virus in an avian model | Q43714146 | ||
| Electrophoretic analysis of iodine-labeled influenza virus RNA segments | Q43815502 | ||
| Effects of sialylation of influenza virions on their interactions with host cells and erythrocytes | Q44081932 | ||
| 2,3-didehydro-2,4-dideoxy-4-guanidino-N-acetyl-D-neuraminic acid (4-guanidino-Neu5Ac2en) is a slow-binding inhibitor of sialidase from both influenza A virus and influenza B virus | Q45772671 | ||
| Effects of hexose starvation and the role of sialic acid in influenza virus release | Q45794047 | ||
| Evidence for host-cell selection of influenza virus antigenic variants | Q45804806 | ||
| Susceptibility of different strains of influenza A virus to the inhibitory effects of 2-deoxy-2,3-dehydro-n-trifluoracetylneuraminic acid (FANA). | Q45883558 | ||
| Amantadine-resistance as a Genetic Marker for Influenza Viruses | Q54595307 | ||
| In vivo Selection of an Influenza A2 Strain resistant to Amantadine | Q71478276 | ||
| Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position | Q72895734 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | influenza A virus | Q834390 |
| P304 | page(s) | 1818-1827 | |
| P577 | publication date | 1996-03-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en | |
| P478 | volume | 70 |
| Q90598908 | A Quinolinone Compound Inhibiting the Oligomerization of Nucleoprotein of Influenza A Virus Prevents the Selection of Escape Mutants |
| Q44497218 | A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding |
| Q33842791 | A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity |
| Q30329168 | Amino acids responsible for the absolute sialidase activity of the influenza A virus neuraminidase: relationship to growth in the duck intestine. |
| Q92735178 | Antiviral activity of ethanol extract of Geranii Herba and its components against influenza viruses via neuraminidase inhibition |
| Q93238882 | Antiviral agents against respiratory viruses |
| Q57815887 | Antiviral resistance markers in influenza virus sequences in Mexico, 2000-2017 |
| Q30408116 | Antiviral strategies for pandemic and seasonal influenza |
| Q33783146 | Attenuation of influenza A virus mRNA levels by promoter mutations |
| Q33806746 | Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus |
| Q35882160 | Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. |
| Q28369317 | Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. |
| Q35005209 | Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir |
| Q40729107 | Correlation between levels of apoptosis, levels of infection and haemagglutinin receptor binding interaction of various subtypes of influenza virus: does the viral neuraminidase have a role in these associations |
| Q30308218 | Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay |
| Q27760264 | Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase |
| Q30438033 | Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors |
| Q27314689 | Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets |
| Q40004651 | Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in Mallard ducks |
| Q33981934 | Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals |
| Q30336347 | Evolutional analysis of human influenza A virus N2 neuraminidase genes based on the transition of the low-pH stability of sialidase activity. |
| Q30354224 | Evolutionary interactions between haemagglutinin and neuraminidase in avian influenza. |
| Q57726212 | Expression of a foreign gene by stable recombinant influenza viruses harboring a dicistronic genomic segment with an internal promoter |
| Q37713074 | Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. |
| Q28379467 | Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140. |
| Q27650325 | HIV-1 Protease Inhibitors from Inverse Design in the Substrate Envelope Exhibit Subnanomolar Binding to Drug-Resistant Variants |
| Q28472513 | Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses |
| Q36770792 | Identification and characterization of influenza variants resistant to a viral endonuclease inhibitor. |
| Q33590644 | Identification of influenza A nucleoprotein as an antiviral target |
| Q52565527 | Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease Inhibitors. |
| Q35024169 | Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses |
| Q39563269 | Importance of viral genomic composition in modulating glycoprotein content on the surface of influenza virus particles. |
| Q42755170 | Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics |
| Q30453278 | In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. |
| Q33787108 | Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice |
| Q35546249 | Influenza Therapy |
| Q38188084 | Influenza reverse genetics: dissecting immunity and pathogenesis |
| Q30305461 | Influenza virus neuraminidase inhibitors |
| Q79340361 | Influenza virus resistance to neuraminidase inhibitors |
| Q33922846 | Influenza virus sialidase: a target for drug discovery. |
| Q38311181 | Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics |
| Q45743666 | Intergenic HA-NA interactions in influenza A virus: postreassortment substitutions of charged amino acid in the hemagglutinin of different subtypes |
| Q36845779 | Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site. |
| Q43176181 | Low pathogenicity H5N2 avian influenza outbreak in Japan during the 2005-2006. |
| Q36090658 | Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance |
| Q39671211 | Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir |
| Q40138039 | Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms |
| Q28263525 | Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors |
| Q33819172 | Mutation of neuraminidase cysteine residues yields temperature-sensitive influenza viruses |
| Q39577999 | Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors |
| Q34077100 | Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility |
| Q44057778 | Neuraminidase inhibitors as antivirals |
| Q30472797 | New approaches to influenza chemotherapy. Neuraminidase inhibitors |
| Q28548477 | Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza Viruses |
| Q34196642 | Oseltamivir: a review of its use in influenza |
| Q34405859 | Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181 |
| Q30450742 | Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors |
| Q40424441 | Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen |
| Q30367861 | Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors. |
| Q40354600 | Recombinant influenza A viruses harboring optimized dicistronic NA segment with an extended native 5' terminal sequence: induction of heterospecific B and T cell responses in mice |
| Q28730182 | Rescue of a H3N2 influenza virus containing a deficient neuraminidase protein by a hemagglutinin with a low receptor-binding affinity |
| Q22305941 | Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors |
| Q45036693 | Resistant influenza A viruses in children treated with oseltamivir: descriptive study |
| Q30359766 | Role of combination antiviral therapy in pandemic influenza and stockpiling implications. |
| Q40912594 | Sialic acids in molecular and cellular interactions |
| Q28391618 | Spherical influenza viruses have a fitness advantage in embryonated eggs, while filament-producing strains are selected in vivo |
| Q36870919 | Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. |
| Q30438502 | Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors |
| Q28542440 | The N-terminal fragment of a PB2 subunit from the influenza A virus (A/Hong Kong/156/1997 H5N1) effectively inhibits RNP activity and viral replication |
| Q30397216 | The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients |
| Q40837861 | The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses |
| Q30364454 | Transmission in the guinea pig model. |
| Q30363382 | Up to new tricks - a review of cross-species transmission of influenza A viruses. |
| Q34229084 | Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza |
| Q33978456 | Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies |
| Q33768776 | Zanamivir: a review of its use in influenza |
| Q34492611 | Zanamivir: an update of its use in influenza |
| Q28344586 | Zanamivir: from drug design to the clinic |
Search more.